<DOC>
	<DOCNO>NCT01206816</DOCNO>
	<brief_summary>The primary objective current study investigate Maximum Tolerated Dose ( MTD ) term safety tolerability combination BI 6727 BIBW 2992 , patient advance metastatic solid tumour . Dosages BI 6727 BIBW 2992 vary establish MTD combination . Two combination treatment schedule test , MTD combination determine . Secondary objective exploration pharmacokinetics , overall safety preliminary efficacy .</brief_summary>
	<brief_title>An Open Label Phase I Dose Escalation Trial Intravenous BI 6727 ( Volasertib ) Combination With Oral BIBW 2992 ( Afatinib ) Patients With Advanced Solid Tumours</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : Patients histologically cytologically confirm diagnosis advance , non resectable and/or metastatic , relapsed refractory solid tumour amenable standard therapy therapy proven efficacy exists Eastern Cooperative Oncology Group performance score 0 2 Recovery clinically significant toxicity previous systemic anticancer therapy radiotherapy Exclusion criterion : Serious illness , concomitant nononcological disease mental problem consider investigator incompatible participation trial Known hypersensitivity trial drug excipients Treatment investigational drug active participation interventional trial within 28 day first administration trial drug ( ) concomitantly trial Major surgery radiotherapy within 28 day start therapy concomitantly trial Systemic anticancer therapy within 28 day start therapy concomitantly trial Requirements treatment prohibit concomitant medication Active infectious disease know HIV I/II infection Gastrointestinal disorder may interfere absorption study drug chronic diarrhoea Active brain metastasis History presence cardiovascular abnormality deem clinically relevant investigator Cardial leave ventricular function rest ejection fraction &lt; 50 % Inadequate hepatic , renal haematologic organ function QT prolongation deem clinically relevant investigator Active alcohol drug abuse Women childbearing potential men able father child unwilling use medically acceptable method contraception trial 28 day thereafter Pregnancy breastfeed Patients unable comply protocol Patients know preexist interstitial lung disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>